Investor Relations

Nemaura Medical (NASDAQ:NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their glucose levels as compared to an HbA1c reading. Insulin users can adjunctively use sugarBEAT® when calibrated with a finger-stick glucose reading.

SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods of up to 24 hours.

Please click here to view our Fact Sheet

Please click here to view our Corporate Presentation.

 

Continuous Glucose Monitoring (CGM) Total Addressable Market (TAM) – Key Points:

– The global TAM for CGM is estimated at $82Bn per annum, consisting of (i) $12.7Bn for Type I insulin users (5% of diabetics), (ii) $38.0Bn for Type II insulin users (15% of diabetics) and (iii) $31.4Bn for Type II non-insulin users (80% of diabetics).1 These numbers exclude the pre-diabetic population which is estimated at nearly three times as large as the diabetic population.

– CGM currently has low adoption rates amongst insulin users (negligible use amongst non-insulin users) and is growing rapidly. The U.S. is the largest market with estimated 2.6% (630,000 users) penetration of diagnosed diabetic market (24.6M), representing annual growth of 117% over 2017 (290,000 users). 1

– Given sugarBEAT ® is (i) non-invasive, (ii) affordable and (iii) flexible, it is expected to have wider appeal to (i) non-insulin using diabetics, (ii) pre-diabetics and (iii) a section of insulin-users who dislike competitor CGMs owing to their (i) invasiveness, (ii) cost and (iii) inflexibility

1 PiperJaffray Company Note DXCM Sep 5, 2018

 


NASDAQ:NMRD - Key Points:

  • - Nemaura Medical Inc. was spun out from founding company and listed on the OTC in Q4 2013, and subsequently uplisted to NASDAQ in Q1 2018
  • - SugarBEAT® predecessor device (based on wrist-watch format) received CE Mark approval in Q1 2016
  • - Submitted current sugarBEAT® format (wireless skin-patch) for date for CE Mark review in Q1 2018
  • - SugarBEAT® completed 525 patient day (75 patients x 7 days) European clinical trial programme in Q4 2017
  • - SugarBEAT® launch due 2018 initially in United Kingdom, followed shortly thereafter by key European countries
  • - Licensee agreement with Dallas Burston Ethitronix Limited (DBE) to market sugarBEAT® throughout United Kingdom and Ireland
  • - DBE was founded by Dr. Dallas Burston (MBBS), a pharmaceutical marketing entrepreneur specialising in selling breakthrough medical products into European markets
  • - Dr. Burston has generated $200M+ by selling some of the previous medical sales companies he founded onto big pharma (for example DB Ashbourne Limited and Ashbourne Pharmaceuticals Limited)
  • - SugarBEAT® expected to complete 525 patient day (75 patients x 7 days) US FDA clinical trial programme in Q1 2019. Please click here to view interim data sets
  • - SugarBEAT® seeks to address two core markets. Firstly, as an adjunctive Continuous Glucose Monitor (CGM) by insulin using persons with diabetes who dislike competitor CGMs owing to their invasiveness, cost and inflexibility. Secondly, as a non-invasive glucose trending device for all persons with diabetes and pre-diabetics, providing an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their sugar levels as compared to a HbA1c reading.
  • - For more information about sugarBEAT®, please visit www.sugarBEAT.com

Stay informed

  • This field is for validation purposes and should be left unchanged.